… Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease
affecting … A new observation is that PMR may appear as a side effect of cancer treatment with …

… Proposed therapeutic algorithm for the treatment of polymyalgia rheumatica (PMR). PDN
indicates prednisone. *The 2008 International Consensus Classification Criteria 47 are …

… SUMMARY Polymyalgia rheumatica (PMR) is considered to be a benign disease bysome, …
similar treatment to giant cell arteritis (GCA). The progress of 85 patients with PMR who …

… initial treatment. Their scope is to provide advice for the diagnosis of PMR, management
and … Development of classification criteria for polymyalgia rheumatica (PMR): results from an …

… If NSAIDs do not adequately control PMR clinical manifestations in 2–4 weeks, CS should …
CS treatment should alert physicians to question the diagnosis. A common treatment schedule …

… There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect
to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic …

… Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by bilateral pain
involving predominantly the shoulders and proximal aspects of the arms and less commonly …

… One randomized controlled trial suggested that MTX can be effective in the treatment of
PMR when drug is started at disease onset and given for at least 1 year at a dose of at least 10 …

… Polymyalgia rheumatica (PMR) typically manifests as inflammatory pain in the shoulder and/or
… simulate PMR, including diseases that carry a grim prognosis or require urgent treatment. …

… There is still a wide heterogeneity in the methods used to treat polymyalgia rheumatica (PMR)
that may be subject to personal experience, the setting in which it is managed (ie, primary …